MY157955A - Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody - Google Patents

Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody

Info

Publication number
MY157955A
MY157955A MYPI20063118A MYPI20063118A MY157955A MY 157955 A MY157955 A MY 157955A MY PI20063118 A MYPI20063118 A MY PI20063118A MY PI20063118 A MYPI20063118 A MY PI20063118A MY 157955 A MY157955 A MY 157955A
Authority
MY
Malaysia
Prior art keywords
therapeutic antibody
target antigen
detection
absence
sample
Prior art date
Application number
MYPI20063118A
Other languages
English (en)
Inventor
Helmut Lenz
Werner Scheuer
Martina Thier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MY157955A publication Critical patent/MY157955A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MYPI20063118A 2005-07-06 2006-06-29 Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody MY157955A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05014618 2005-07-06
EP06004447 2006-03-06

Publications (1)

Publication Number Publication Date
MY157955A true MY157955A (en) 2016-08-30

Family

ID=36922121

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20063118A MY157955A (en) 2005-07-06 2006-06-29 Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody

Country Status (19)

Country Link
US (1) US20070009976A1 (cg-RX-API-DMAC7.html)
EP (2) EP2194380A3 (cg-RX-API-DMAC7.html)
JP (1) JP2008545145A (cg-RX-API-DMAC7.html)
KR (1) KR20080016939A (cg-RX-API-DMAC7.html)
AR (1) AR053948A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006265275A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0612591A2 (cg-RX-API-DMAC7.html)
CA (1) CA2613187A1 (cg-RX-API-DMAC7.html)
CR (1) CR9635A (cg-RX-API-DMAC7.html)
EC (1) ECSP088081A (cg-RX-API-DMAC7.html)
IL (1) IL188317A0 (cg-RX-API-DMAC7.html)
MA (1) MA29730B1 (cg-RX-API-DMAC7.html)
MX (1) MX2008000277A (cg-RX-API-DMAC7.html)
MY (1) MY157955A (cg-RX-API-DMAC7.html)
NO (1) NO20076662L (cg-RX-API-DMAC7.html)
NZ (1) NZ564471A (cg-RX-API-DMAC7.html)
RU (1) RU2008103608A (cg-RX-API-DMAC7.html)
TW (1) TWI312864B (cg-RX-API-DMAC7.html)
WO (1) WO2007003420A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001264696B2 (en) 2000-05-19 2007-01-04 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
ZA200701234B (en) * 2004-07-22 2008-12-31 Genentech Inc HER2 antibody composition
US7936392B2 (en) 2004-10-01 2011-05-03 The Board Of Trustees Of The Leland Stanford Junior University Imaging arrangements and methods therefor
WO2007092545A2 (en) 2006-02-07 2007-08-16 The Board Of Trustees Of The Leland Stanford Junior University Variable imaging arrangements and methods therefor
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2596133C (en) 2005-02-23 2016-11-15 Genentech, Inc. Extending time to disease progression or survival in cancer patients
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US8358354B2 (en) 2009-01-26 2013-01-22 The Board Of Trustees Of The Leland Stanford Junior University Correction of optical abberations
CA2677108A1 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her inhibitor
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
PT4403228T (pt) 2011-10-14 2025-10-07 Hoffmann La Roche Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
KR101327542B1 (ko) * 2012-03-15 2013-11-08 광주과학기술원 양자점 기반의 경쟁 면역분석법 및 다중 유세포 분석법을 이용한 시료 중 오염물질의 검출 방법
AU2012232949B2 (en) * 2012-09-28 2014-07-03 Willowtree Holdings Pty Ltd Temporary bulkhead
US9815904B2 (en) 2013-04-16 2017-11-14 Genetech, Inc. Pertuzumab variants and evaluation thereof
KR20160141857A (ko) 2014-04-25 2016-12-09 제넨테크, 인크. 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
PT3302551T (pt) 2015-05-30 2024-08-21 H Hoffnabb La Roche Ag Métodos de tratamento do cancro da mama metastático positivo para her2 não tratado previamente
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
US20180221481A1 (en) 2016-12-28 2018-08-09 Genentech, Inc. Treatment of advanced her2 expressing cancer
LT3570884T (lt) 2017-01-17 2020-12-10 Genentech, Inc. Poodinės her2 antikūnų kompozicijos
JP6992081B2 (ja) 2017-03-02 2022-02-03 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性乳癌のアジュバント治療
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
MX2022015884A (es) 2020-06-29 2023-04-03 Genentech Inc Combinacion de dosis fija de pertuzumab mas trastuzumab.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA2103059C (en) * 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
CN101412758A (zh) 1996-10-18 2009-04-22 基因技术股份有限公司 抗ErbB2抗体
JP4424987B2 (ja) 2001-09-20 2010-03-03 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Ｅｌｉｓａアッセイを用いた循環する治療抗体、抗原および抗原／抗体複合体の測定
AU2003273218C1 (en) * 2002-07-15 2019-01-17 F. Hoffmann - La Roche Ag Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies

Also Published As

Publication number Publication date
EP1902315A1 (en) 2008-03-26
CA2613187A1 (en) 2007-01-11
AR053948A1 (es) 2007-05-23
MX2008000277A (es) 2008-03-24
KR20080016939A (ko) 2008-02-22
CR9635A (es) 2008-02-20
NZ564471A (en) 2010-04-30
US20070009976A1 (en) 2007-01-11
ECSP088081A (es) 2008-02-20
NO20076662L (no) 2008-04-03
AU2006265275A1 (en) 2007-01-11
JP2008545145A (ja) 2008-12-11
MA29730B1 (fr) 2008-09-01
EP2194380A3 (en) 2010-07-14
BRPI0612591A2 (pt) 2010-11-23
EP2194380A2 (en) 2010-06-09
TW200741203A (en) 2007-11-01
WO2007003420A1 (en) 2007-01-11
IL188317A0 (en) 2008-04-13
RU2008103608A (ru) 2009-08-20
TWI312864B (en) 2009-08-01

Similar Documents

Publication Publication Date Title
MY157955A (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
NZ609824A (en) Immunochromatography devices, methods and kits
WO2008070229A3 (en) Detection of pathogenic aggregates of protein in a sample by homologous elisa
MX363403B (es) Inmumoensayo con interferencia suprimida para la deteccion de anticuerpos anti-farmacos en muestras de suero.
WO2002037112A3 (en) Detection of ovarian cancer
WO2009023331A3 (en) Antibodies and improved test sample handling methods for use in assays for myeloperoxidase
MY145455A (en) Diagnostic biomolecule(s)
TW200801202A (en) Alpha-enolase specific antibody and method of use
MX2009012048A (es) Eliminacion de interferencia en inmunoensayos ocasionada por anticuerpos de anti-carbohidrato.
WO2006002243A3 (en) Methods of oligosaccharide profiling for the detection of cancer
WO2011008831A3 (en) Mass tags for spectrometric analysis of immunoglobulins
WO2009111572A3 (en) Cell, method and kit for conducting an assay for neutralizing antibodies
SG164389A1 (en) Detection of a therapeutic antibody in an experimental animal
WO2007147141A3 (en) Methods for detecting molecular complexes
WO2007024735A3 (en) Method and antibodies for detecting nitrofuran
WO2008136510A1 (ja) 自己免疫性膵炎及び劇症１型糖尿病の検査方法及び検査試薬
WO2006004958A3 (en) Detection or measurement of antibodies to antigenic proteins in biological tissues or samples
WO2007037910A3 (en) Specific removal of activated immune cells
MY151190A (en) Method of detecting pork in processed food and detection kit therefor
WO2012141792A3 (en) Adiponectin receptor c-terminal fragments (ctf)-immunoglobulin
GB9913819D0 (en) Assay
WO2006060188A3 (en) Anti-tenascin monoclonal antibody immunoassays and diagnostic kits
GB0718603D0 (en) Methods
WO2007071250A3 (en) Method for detection of l523s expression in biological samples
IL201677A0 (en) Multi-immunoaffinity based antigen identification